Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-21

Clinical Trial Update: A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis [Phase 3]

View source ↗

Summary

Phase 3 trial of flurbiprofen 8.75 mg lozenge in pharyngitis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Flurbiprofen 8.75 mg lozenge (flurbiprofen)

Snippet

Sponsor: Reckitt Benckiser LLC | Conditions: Pharyngitis | Phase 3 | Status: COMPLETED | Results posted: 2017-09-21